Segui
Laura Raffals
Laura Raffals
Associate Professor of Medicine, Mayo Clinic
Email verificata su mayo.edu
Titolo
Citata da
Citata da
Anno
Appropriate therapeutic drug monitoring of biologic agents for patients with inflammatory bowel diseases
K Papamichael, AS Cheifetz, GY Melmed, PM Irving, NV Casteele, ...
Clinical Gastroenterology and Hepatology 17 (9), 1655-1668. e3, 2019
2752019
Depression is associated with more aggressive inflammatory bowel disease
B Kochar, EL Barnes, MD Long, KC Cushing, J Galanko, CF Martin, ...
Official journal of the American College of Gastroenterology| ACG 113 (1), 80-85, 2018
1602018
A gene-targeted approach to investigate the intestinal butyrate-producing bacterialcommunity
M Vital, CR Penton, Q Wang, VB Young, DA Antonopoulos, ML Sogin, ...
Microbiome 1, 1-14, 2013
1532013
Results at up to 30 years after ileal pouch–anal anastomosis for chronic ulcerative colitis
AL Lightner, KL Mathis, EJ Dozois, D Hahnsloser, EV Loftus Jr, LE Raffals, ...
Inflammatory bowel diseases 23 (5), 781-790, 2017
1332017
Effects of concomitant immunomodulator therapy on efficacy and safety of anti–tumor necrosis factor therapy for Crohn’s disease: a meta-analysis of placebo-controlled trials
JL Jones, GG Kaplan, L Peyrin-Biroulet, L Baidoo, S Devlin, GY Melmed, ...
Clinical Gastroenterology and Hepatology 13 (13), 2233-2240. e2, 2015
1302015
Postoperative outcomes in vedolizumab-treated patients undergoing abdominal operations for inflammatory bowel disease
AL Lightner, LE Raffals, KL Mathis, RR Cima, CS Tse, JH Pemberton, ...
Journal of Crohn's and Colitis 11 (2), 185-190, 2017
1252017
Predictors of health-related quality of life and adherence in Crohn’s disease and ulcerative colitis: implications for clinical management
A Tabibian, JH Tabibian, LJ Beckman, LL Raffals, KA Papadakis, ...
Digestive diseases and sciences 60, 1366-1374, 2015
1052015
Comparison of brush and biopsy sampling methods of the ileal pouch for assessment of mucosa-associated microbiota of human subjects
SM Huse, VB Young, HG Morrison, DA Antonopoulos, J Kwon, S Dalal, ...
Microbiome 2, 1-8, 2014
992014
Postoperative outcomes in ustekinumab-treated patients undergoing abdominal operations for Crohn’s disease
AL Lightner, NP McKenna, CS Tse, N Hyman, R Smith, G Ovsepyan, ...
Journal of Crohn's and Colitis 12 (4), 402-407, 2018
872018
An increased abundance of Clostridiaceae characterizes arthritis in inflammatory bowel disease and rheumatoid arthritis: a cross-sectional study
DA Muñiz Pedrogo, J Chen, B Hillmann, P Jeraldo, G Al-Ghalith, V Taneja, ...
Inflammatory bowel diseases 25 (5), 902-913, 2019
762019
The microbiome in Crohn's disease: role in pathogenesis and role of microbiome replacement therapies
S Khanna, LE Raffals
Gastroenterology Clinics 46 (3), 481-492, 2017
732017
Ustekinumab is effective for the treatment of Crohn’s disease of the pouch in a multicenter cohort
KN Weaver, M Gregory, G Syal, P Hoversten, SB Hicks, D Patel, ...
Inflammatory bowel diseases 25 (4), 767-774, 2019
722019
Combination biologic therapy in inflammatory bowel disease: experience from a tertiary care center
L Kwapisz, LE Raffals, DH Bruining, DS Pardi, WJ Tremaine, SV Kane, ...
Clinical Gastroenterology and Hepatology 19 (3), 616-617, 2021
662021
Postoperative outcomes in vedolizumab‐treated Crohn's disease patients undergoing major abdominal operations
AL Lightner, NP McKenna, CS Tse, LE Raffals, EV Loftus Jr, KL Mathis
Alimentary pharmacology & therapeutics 47 (5), 573-580, 2018
652018
Effects of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease
CS Tse, EV Loftus Jr, LE Raffals, AA Gossard, AL Lightner
Alimentary pharmacology & therapeutics 48 (2), 190-195, 2018
632018
Efficacy of vedolizumab for refractory pouchitis of the ileo-anal pouch: results from a multicenter US cohort
M Gregory, KN Weaver, P Hoversten, SB Hicks, D Patel, MA Ciorba, ...
Inflammatory bowel diseases 25 (9), 1569-1576, 2019
612019
Crohn's disease of the esophagus: clinical features and treatment outcomes in the biologic era
KM De Felice, DA Katzka, LE Raffals
Inflammatory bowel diseases 21 (9), 2106-2113, 2015
602015
Hyperbaric oxygen therapy is well tolerated and effective for ulcerative colitis patients hospitalized for moderate-severe flares: a phase 2A pilot multi-center, randomized …
PS Dulai, JC Buckey Jr, LE Raffals, JM Swoger, PL Claus, K O'Toole, ...
Official journal of the American College of Gastroenterology| ACG 113 (10 …, 2018
592018
Antibiotic use and new-onset inflammatory bowel disease in Olmsted County, Minnesota: a population-based case-control study
S Aniwan, WJ Tremaine, LE Raffals, SV Kane, EV Loftus Jr
Journal of Crohn's and Colitis 12 (2), 137-144, 2018
582018
Variation in treatment of patients with inflammatory bowel diseases at major referral centers in the United States
AN Ananthakrishnan, J Kwon, L Raffals, B Sands, WF Stenson, ...
Clinical Gastroenterology and Hepatology 13 (6), 1197-1200, 2015
582015
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20